A deterministic history of records added to PeptideScanner and preserved profile or record revisions connected through the reviewed Cagrilintide identity.
Crossref dates: June 19, 2026 and August 1, 2026. Checked September 15, 2026. The metadata identifies a connected notice but does not describe its scientific impact.
ClinicalTrials.gov posted a newer version of NCT07220759, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner change date
November 16, 2026
Cited source date
November 16, 2026
Evidence lane
Clinical trials
Summary
Before
PeptideScanner retained ClinicalTrials.gov record NCT07220759 at 2026-08-13T05:52:27.019Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was cagrilintide.
After
PeptideScanner retained ClinicalTrials.gov record NCT07220759 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was cagrilintide.
1. PeptideScanner retained ClinicalTrials.gov record NCT07220759 at 2026-08-13T05:52:27.019Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was cagrilintide. [sources: ctg-observation-nct07220759-2026-08-03-50fb10a6adbd]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07220759-2026-08-03-50fb10a6adbd]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT07220759 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was cagrilintide. [sources: ctg-observation-nct07220759-2026-08-03-50fb10a6adbd-r2]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07220759-2026-08-03-50fb10a6adbd-r2]
We added a plain-language reader guide with cited answers, published trial results from our human evidence review, current ClinicalTrials.gov records, and FDA’s current page on unapproved GLP-1 drugs (content current as of October 1, 2026), which states that cagrilintide cannot be used in compounding.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Status
Before
Investigational
After
In clinical trials; not FDA-approved
Profile summary
Before
A long-acting amylin analogue under study. This profile cites a recruiting ClinicalTrials.gov record.
After
An experimental long-acting amylin analogue from Novo Nordisk, studied alone and combined with semaglutide as CagriSema. FDA says it is not an approved drug and cannot be used in compounding.
Evidence note
Before
ClinicalTrials.gov lists a Novo Nordisk pediatric study as recruiting, updated July 17, 2026.
After
A published Phase 2 trial of cagrilintide alone and large Phase 3 trials of the cagrilintide-semaglutide combination report weight loss; combination results cannot be credited to cagrilintide alone. FDA states that cagrilintide has not been found safe and effective for any condition.
Showing the latest 14 additions by PeptideScanner publication date; the complete connected record set remains available on the cross-source timeline. Most recent addition: September 9, 2026.
PeptideScanner retained ClinicalTrials.gov record NCT07411560 at 2026-07-30T16:20:49.304Z. Its registry update date was 2026-04-13, and PeptideScanner's reviewed identity mapping was cagrilintide.
PeptideScanner retained ClinicalTrials.gov record NCT07607587 at 2026-07-30T16:19:03.059Z. Its registry update date was 2026-06-25, and PeptideScanner's reviewed identity mapping was cagrilintide.
PeptideScanner retained ClinicalTrials.gov record NCT07220759 at 2026-08-13T05:52:27.019Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was cagrilintide.
PeptideScanner retained ClinicalTrials.gov record NCT07745504 at 2026-08-13T05:52:27.004Z. Its registry update date was 2026-08-04, and PeptideScanner's reviewed identity mapping was cagrilintide.
PeptideScanner retained PubMed bibliographic metadata for PMID 40609154 at 2026-07-30T18:24:19.064Z. PubMed recorded a metadata revision date of 2025-08-26 and an Entrez history date of 2025-07-03. PeptideScanner associated this retained record with the identity slug cagrilintide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 40847076 at 2026-07-30T16:31:19.891Z. PubMed recorded a metadata revision date of 2026-01-06 and an Entrez history date of 2025-08-22. PeptideScanner associated this retained record with the identity slug cagrilintide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 36242844 at 2026-07-30T19:34:05.168Z. PubMed recorded a metadata revision date of 2022-11-29 and an Entrez history date of 2022-10-15. PeptideScanner associated this retained record with the identity slug cagrilintide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 39868309 at 2026-07-30T16:14:10.807Z. PubMed recorded a metadata revision date of 2026-06-25 and an Entrez history date of 2025-01-27. PeptideScanner associated this retained record with the identity slug cagrilintide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 40204768 at 2026-07-30T18:29:52.187Z. PubMed recorded a metadata revision date of 2025-04-12 and an Entrez history date of 2025-04-09. PeptideScanner associated this retained record with the identity slug cagrilintide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 42260118 at 2026-07-30T16:14:18.129Z. PubMed recorded a metadata revision date of 2026-06-25 and an Entrez history date of 2026-06-08. PeptideScanner associated this retained record with the identity slug cagrilintide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT05804162 at 2026-07-30T18:38:25.523Z. Its registry update date was 2024-11-01, and PeptideScanner's reviewed identity mapping was cagrilintide.
PeptideScanner retained ClinicalTrials.gov record NCT07557953 at 2026-07-30T16:19:36.906Z. Its registry update date was 2026-05-15, and PeptideScanner's reviewed identity mapping was cagrilintide.
PeptideScanner retained ClinicalTrials.gov record NCT07220642 at 2026-07-30T16:19:03.066Z. Its registry update date was 2026-06-30, and PeptideScanner's reviewed identity mapping was cagrilintide.